Erik Johan Frostegård
Direttore/Membro del Consiglio presso ANNEXIN PHARMACEUTICALS AB
Posizioni attive di Erik Johan Frostegård
Società | Posizione | Inizio | Fine |
---|---|---|---|
ANNEXIN PHARMACEUTICALS AB | Direttore/Membro del Consiglio | 01/01/2016 | - |
Karolinska Institutet | Corporate Officer/Principal | - | - |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Corporate Officer/Principal | - | - |
Storia della carriera di Erik Johan Frostegård
Precedenti posizioni note di Erik Johan Frostegård
Società | Posizione | Inizio | Fine |
---|---|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Direttore/Membro del Consiglio | 01/01/2002 | - |
Fondatore | 01/01/2002 | - |
Statistiche
Distribuzione geografica
Svezia | 5 |
Posizioni
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Founder | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ANNEXIN PHARMACEUTICALS AB | Health Technology |
Aziende private | 2 |
---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Health Services |